Showing results (2961-2970 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|January 6, 2016
Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in ratsXuhui Bao, Vidyalakshmi Chandramohan, Randall P Reynolds, et al.Investigational New Drugs|October 9, 2015
Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma modelMaurizio Viale, Marta Rossi, Eleonora Russo, et al.Investigational New Drugs|November 11, 2015
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignanciesÅke Berglund, Anders Ullén, Alla Lisyanskaya, et al.Investigational New Drugs|March 19, 2016
Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell linesLea S Flocke, Robert Trondl, Michael A Jakupec, et al.Investigational New Drugs|March 1, 2016
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancerChristos E Kyriakopoulos, Elisabeth I Heath, Jens C Eickhoff, et al.Investigational New Drugs|April 24, 2016
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatinChristopher C Coss, Amanda Jones, James T DaltonInvestigational New Drugs|April 15, 2016
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187Eric X Chen, Derek J Jonker, Lillian L Siu, et al.Investigational New Drugs|April 15, 2016
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapiesYaghoub Safdari, Vahideh Ahmadzadeh, Safar FarajniaInvestigational New Drugs|December 4, 2014
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancerDaniel J Crona, Young E WhangInvestigational New Drugs|May 25, 2019
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancerBo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, et al.Pageof 372